FDA Eyes Regulatory Oversight Of Bolus Calculator Apps
This article was originally published in The Gray Sheet
Executive Summary
During a recent panel discussion on bolus insulin calculator apps, experts called on FDA to establish some oversight, but said precise steps should vary depending on whether the app is intended to incorporate new data sources.
You may also be interested in...
FDA Catches Heat For Plans To Raise Standards For Hospital Glucose Meters
An FDA draft guidance issued earlier this year on hospital glucose meters has attracted an unusual amount of attention, including criticism from clinicians, companies and others who worry it could cut off access to point-of-care glucose testing in patient cases where it is needed. The agency says it is taking appropriate measures to address a safety issue, and that some of the criticism is misdirected.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.